Stem cells and cerebral palsy: more than 15 years of research

Stem cells and cerebral palsy: more than 15 years of research
Posted on Mon 20 Dec 2021

In their latest blog piece, Cerebral Palsy Alliance Research Institute's Dr Madison Paton and Dr Megan Finch-Edmondson explore just what we've learned from 15 years of stem cell studies involving people living with cerebral palsy - and where to next.

Our team recently summarised all available human research to find out how many people with cerebral palsy have been treated with stem cells. Incredibly, we found that more than 2,400 people have been treated since 2004. With all this information, what have we learnt, and where to next?

What have we learnt?

  • A number of stem cell therapies are currently under investigation for cerebral palsy. We divided these into 5 categories for analysis (Figure 1, Cell Type) and counted all participants treated in a research setting. The number treated with each cell type, over different phases of research are shown.
  • There have been 77 studies that are either completed or underway, with 2,427 people with cerebral palsy treated. This total number does not include those seeking treatments via private clinics and unpublished clinical trials that are not registered on clinicaltrials.gov.  
  • Umbilical cord blood is the most well-studied cell therapy. This treatment is sourced from the placenta after a baby is born. Umbilical cord blood is rich in many stem and immune cells. Importantly, previous studies have shown that umbilical cord blood used as a treatment for children with cerebral palsy is safe and can provide small benefits in motor function alongside rehabilitation (Novak et all 2016).

Research into other stem cell types are progressing. This includes mesenchymal stem cells, haematopoietic or blood-forming stem cells, and neural (brain) and neural-like stem cells.

Whilst evidence is mounting, no stem cell treatment for cerebral palsy is approved for use anywhere in the world.

The majority of research is still in early Phase I (i.e. is it safe?) or Phase II (i.e. is it worthwhile?) studies.

More research is required.

Figure 1: Number of participants treated with cerebral palsy over 15 years of stem cell research

adapted from Paton, M.C., Finch-Edmondson, M., et al (2021)

 

Where to next?

A missing piece to progress stem cell treatments for cerebral palsy are Phase III clinical trials. Phase III clinical trials help us to answer, if we treat an even larger group of people, can we still show safety and effectiveness? You can learn more about the research pipeline and trial phases here.

We believe the time is right for a Phase III trial using umbilical cord blood. This research will help us understand if umbilical cord blood is effective in improving movement for those with cerebral palsy in a large population. A Phase III trial is the missing piece to enable regulatory approval and access to stem cell treatment, both overseas and in Australia.

Whilst we believe that umbilical cord blood is ready for large Phase III trials, others stem cell types need to first move through earlier phases of the clinical trial pipeline. This will help to answer questions such as “how does it work?”, “what is the best dose?”, “how can we give the treatment?”, and “when do we give the treatment?”. These unanswered questions now shape the field’s future research directions.

You can learn more about the 15 years of stem cell research for cerebral palsy in our recent publication:

Reference: Paton, M.C., Finch-Edmondson, M., Fahey, M.C., London, J., Badawi, N. and Novak, I. (2021), Fifteen years of human research using stem cells for cerebral palsy: A review of the research landscape. J Paediatr Child Health, 57: 295-296.

To read more about stem cells and cerebral palsy research, read Madison and Megan's previous blog posts: 

Instead of having the fun-filled family Christmas I'd planned, we spent Christmas with COVID. Over the course of a week, all five of us got it, resigned to the fact that isolating from each other at this time of year, especially given how much I rely on other people for self-care, was a pretty fruitless exercise. 

An update from CEO Rob White on how CPA is supporting and protecting our clients during COVID-19, and CPA therapy and services in January 2022.